Novalgine (Metamizole Sodium)

Metamizole Sodium, the active ingredient in Novalgine, is a non‑opioid analgesic presented as an oral formulation for oral use. It is employed to relieve moderate to severe pain and to reduce high fever in adult patients.

GNH USA supplies Novalgine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novalgine, a pyrazolone‑derived analgesic, is used in conditions where pain or fever require rapid control.

Acute pain: provides effective analgesia for short‑term severe pain such as postoperative or trauma‑related discomfort. Fever: lowers elevated body temperature when antipyretic therapy is needed. Colicky abdominal pain: eases spasmodic pain associated with gastrointestinal cramps.

Metamizole Sodium may cause a range of adverse reactions, from mild to severe. Monitoring for side effects is recommended during therapy.

Common Side Effects: - Nausea or vomiting - Dizziness or light‑headedness - Mild skin rash or itching - Transient hypotension - Elevated liver enzymes - Gastrointestinal discomfort

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count) - Severe allergic reactions (anaphylaxis, angioedema) - Hepatotoxicity - Blood dyscrasias such as thrombocytopenia - Renal impairment in susceptible individuals

Before initiating therapy with Novalgine, consider the following precautions: - Assess blood counts: baseline and periodic monitoring for agranulocytosis. - Evaluate liver and kidney function: adjust use in hepatic or renal impairment. - Review allergy history: avoid in patients with known hypersensitivity to pyrazolones. - Caution in elderly patients: increased susceptibility to hypotension and renal effects. - Avoid concurrent use with other myelosuppressive agents. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Metamizole Sodium can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Immunosuppressants (e.g., azathioprine, cyclophosphamide): heightened risk of bone‑marrow suppression. - Other non‑opioid analgesics (e.g., NSAIDs, acetaminophen): additive toxicity to liver or kidneys.

Moderate Interactions (Monitor Closely): - ACE inhibitors or diuretics: may potentiate hypotensive effects. - Antihypertensive agents: monitor blood pressure for additive lowering. - Drugs affecting uric acid metabolism (e.g., allopurinol): watch for altered renal handling.